Today: 10 July 2026
Browse Category

NASDAQ:ERNA 29 October 2025 - 12 May 2026

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Therapeutics shot higher on Tuesday, though the trading action left plenty of questions. The move was really a textbook biotech squeeze, sparked by fresh investor focus on ERNA-101, their preclinical cell therapy for ovarian cancer. The stock’s thin float and last month’s reverse split set the stage. As of 3:50 p.m. ET, shares were changing hands at $11.43, marking a gain of 58.5%. ERNA swung as high as $15.58, with an intraday floor at $6.86.
12 May 2026
··
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Ernexa Therapeutics Inc. reported Wednesday that its lead cell therapy, ERNA-101, paired with PD-1 blockade, wiped out tumors completely and delivered 100% long-term survival in preclinical ovarian cancer studies. “Complete tumor eradication and durable survival,” is how Chief Scientific Officer Robert H. Pierce summed up the results. Chief Executive Sanjeev Luther called the data “beyond expectations.”
6 May 2026
···
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics Inc. – a small Cambridge, MA biotech formerly known as Eterna Therapeutics – saw its stock skyrocket on October 29 after unveiling a major collaboration to advance its cutting-edge cancer therapy. By Wednesday afternoon, ERNA shares were up about 48% as investors piled in on news that Ernexa is partnering with Cellipont Bioservices to scale up ERNA-101 for clinical trialsstocktwits.com. “Shares of Ernexa Therapeutics traded 48% higher on Wednesday afternoon after Cellipont Bioservices announced that it has entered into a collaboration with the company,” Stocktwits reportedstocktwits.com. The stock, which had closed around $1.20 the prior day, surged to roughly $1.80 intraday, marking one of its biggest single-day gains this year.
29 October 2025
··

Stock Market Today

  • Cognex (NASDAQ:CGNX) Gains 1.6%, Trading at 10.6x Sales and Targeting Q2 Revenue Growth
    July 10, 2026, 5:30 PM EDT. Cognex shares rose 1.6% to $66.84 on July 10, 2026, topping the S&P 500 by 0.42%. The machine vision maker is valued at $11.12 billion and trades at 78 times trailing earnings, showing strong growth expectations even with Q2 headwinds. The company's revenue stands at $1.05 billion over the last year, trailing behind Zebra Technologies and Rockwell Automation, but its price-to-sales ratio of 10.6 shows the market is focused on growth. CEO Matt Moschner and CFO Dennis Fehr pointed to disciplined execution, after Q1 revenue jumped 24% and EBITDA doubled. For Q2, Cognex projects $280-$300 million in revenue, aiming for adjusted EBITDA margins of 28% to 31%, with management targeting 16.5% revenue and 68% EPS growth from last year. Tariffs, China's economy, and supply issues still pose risks to the stock's high valuation.
Go toTop